- Start Codon aims to rapidly translate the most disruptive and innovative life science research into successful companies and positive clinical outcomes
- The first cohort of four companies will debut at the Milner Therapeutics Symposium on the 26th June and at OnHelix on the 14th July
News
June 23, 2020 02:01 AM Eastern Daylight Time
Dr Steven Newhouse is the Head of Technical Services at EMBL's European Bioinformatics Institute (EMBL-EBI). He has previously held roles in the leadership of European Grid Infrastructure activities and was a Program Manager in the High Performance Computing (HPC) group in the Windows server division at Microsoft. Dr Newhouse’s role today involves managing teams that bring both new innovations and established technology services from Europe and around the world to further develop and support the life sciences.
- Experienced tech leader Meri Williams joins Healx - the AI-powered, patient-inspired technology company - from challenger bank Monzo, as Chief Technology Officer.
- In her new role, Meri will focus on scaling Healx’s technology and team following their successful Series B raise of $56 million in October 2019.
- Meri’s appointment consolidates Healx’s focus on technical excellence, and is the latest in several senior appointments at Healx over the last few months.
NORWICH, UK - 17 June 2020: Leaf Expression Systems (Leaf), a contract development and manufacturing organisation based in Norwich, UK, has announced today that it has developed a recombinant SARS-CoV-2 N-protein (antigen) to aid research into the Novel Coronavirus (SARS-CoV-2, 2019-nCoV) pandemic.
Research evidences that well-placed public-sector funding in life sciences drives considerable returns to the UK economy and society
AT247 delivers significantly accelerated absorption of insulin compared to best in class treatments NovoRapid® and Fiasp®
Cambridge, UK., 15 June 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, presented positive results for the Phase I clinical trial of its ultra-rapid acting insulin product candidate, AT247, at the American Diabetes Association 80th Scientific Sessions (ADA) virtual meeting. The abstract, #231-OR, is available on the ADA website.
Pharmaceutical and biotech product development consultancy Boyds has hired regulatory professional Dr Lucie Hwang as associate in its award-winning regulatory affairs team that supports clients facilitating the fast and efficient development of medicinal products.
AMSBIO reports on the pioneering work by researchers at the University of Sheffield, UK** to measure the interaction between the SARS-CoV-2 Spike S1 protein receptor binding domain (SARS-CoV-2 S1 RBD) and heparin. This has resulted in a new assay which could be a useful first screen for novel inhibitors of coronavirus infection.
Cambridge, UK, 09 June 2020: CN Bio, a leading cell culture company that has developed single and multi-organ microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery, today announced the publication of co-authored research led by researchers at the University of Cambridge in Nature Metabolism1, identifying a novel pathway that regulates the underlying mechanism of Non-Alcoholic Steatohepatitis (NASH), potentially a new therapeutic target.